158 related articles for article (PubMed ID: 32717431)
1. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients.
Chhabra S; Thapa B; Szabo A; Konings S; D'Souza A; Dhakal B; Jerkins JH; Pasquini MC; Johnson BD; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2011-2017. PubMed ID: 32717431
[TBL] [Abstract][Full Text] [Related]
2. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang EC; Muffly LS; Shiraz P; Shizuru JA; Johnston L; Arai S; Frank MJ; Weng WK; Lowsky R; Rezvani A; Meyer EH; Negrin R; Miklos DB; Sidana S
Transplant Cell Ther; 2021 May; 27(5):405.e1-405.e6. PubMed ID: 33775587
[TBL] [Abstract][Full Text] [Related]
3. Cryopreservation and storage patterns of hematopoietic progenitor stem cells for multiple myeloma.
Benjamin CL; Desai S; Pereira D; Beitinjaneh A; Jimenez A; Goodman M; Lekakis L; Spiegel J; Komanduri KV; Wang TP
Transfus Apher Sci; 2023 Oct; 62(5):103731. PubMed ID: 37236900
[TBL] [Abstract][Full Text] [Related]
4. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
[TBL] [Abstract][Full Text] [Related]
5. Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation.
Makhani SS; Oza SP; Reich-Slotky R; Munshi PN; Biran N; Donato ML; Siegel DS; Vesole DH; Naam S; Rowley SD
Transplant Cell Ther; 2022 Jun; 28(6):306.e1-306.e7. PubMed ID: 35248777
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era.
Arora S; Majhail NS; Liu H
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):200-205. PubMed ID: 30679106
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
[TBL] [Abstract][Full Text] [Related]
8. Analysis of laboratory parameters for optimal autologous peripheral blood stem cell collection from lymphoma and myeloma patients.
Kong JH; Hu Y; Kong SY; Lee SN; Eom HS; Lee H; Lee E; Shim H
J Clin Apher; 2021 Feb; 36(1):135-142. PubMed ID: 33247855
[TBL] [Abstract][Full Text] [Related]
9. Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease.
Tormey CA; Snyder EL; Cooper DL
Transfusion; 2008 Sep; 48(9):1930-3. PubMed ID: 18513256
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the predictive value of the hematopoietic progenitor cell count using an automated hematology analyzer for CD34+ stem cell mobilization and apheresis product yield.
Furundarena JR; Uranga A; Alkorta A; González C; Javier Ferreiro J; Rey M; Aragón L; Urreta I; Emparanza JI; Redín H; Garrido A; Araiz M
Int J Lab Hematol; 2020 Apr; 42(2):170-179. PubMed ID: 31830371
[TBL] [Abstract][Full Text] [Related]
11. Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation.
Pavlů J; Auner HW; Szydlo RM; Sevillano B; Palani R; O'Boyle F; Chaidos A; Jakob C; Kanfer E; MacDonald D; Milojkovic D; Rahemtulla A; Bradshaw A; Olavarria E; Apperley JF; Pello OM
Bone Marrow Transplant; 2017 Dec; 52(12):1599-1601. PubMed ID: 28650454
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia.
Papanikolaou X; Rosenbaum ER; Tyler LN; Sawyer J; Heuck CJ; Barlogie B; Cottler-Fox M
Leukemia; 2014 Apr; 28(4):888-93. PubMed ID: 23852547
[TBL] [Abstract][Full Text] [Related]
13. Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple Myeloma.
Krummradt F; Sauer S; Pavel P; Klein EM; Schmitt A; Kriegsmann M; Jordan K; Müller-Tidow C; Goldschmidt H; Wuchter P; Kriegsmann K
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1589-1596. PubMed ID: 32428735
[TBL] [Abstract][Full Text] [Related]
14. Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study.
Esteghamat NS; Brunson A; Rosenberg AS; Schonfeld SJ; Valcarcel B; Abrahão R; Cooley JJP; Meyer CL; Auletta JJ; Morton LM; Muffly L; Wun T; Keegan THM
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e119-e129. PubMed ID: 38195324
[TBL] [Abstract][Full Text] [Related]
15. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.
Badar T; Dhakal B; Szabo A; Padmanabhan A; Johnson BD; Heidtke S; Esselmann J; Chhabra S; Hamadani M; Hari P; D'Souza A
J Clin Apher; 2019 Dec; 34(6):686-691. PubMed ID: 31566813
[TBL] [Abstract][Full Text] [Related]
16. Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group.
Drozd-Sokołowska J; Waszczuk-Gajda A; Topczewska M; Mańko J; Hus I; Szmigielska-Kapłon A; Nowicki M; Grygoruk-Wiśniowska I; Krawczyk-Kuliś M; Romejko-Jarosińska J; Frączak E; Wróbel T; Piątkowska-Jakubas B; Mądry K; Boguradzki P; Król M; Kozioł M; Hus M; Kopińska A; Dmoszyńska A; Basak GW; Dwilewicz-Trojaczek J
J Clin Apher; 2021 Jun; 36(3):443-453. PubMed ID: 33592119
[TBL] [Abstract][Full Text] [Related]
17. Letter to the Editor Regarding "Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients".
Wolf J; Smythe J; Griffin J
Transplant Cell Ther; 2021 Mar; 27(3):199-200. PubMed ID: 35348115
[No Abstract] [Full Text] [Related]
18. Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.
Maul JT; Stenner-Liewen F; Seifert B; Pfrommer S; Petrausch U; Kiessling MK; Schanz U; Nair G; Mischo A; Taverna C; Schmidt A; Bargetzi M; Stupp R; Renner C; Samaras P
J Clin Apher; 2017 Feb; 32(1):21-26. PubMed ID: 27001243
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
[TBL] [Abstract][Full Text] [Related]
20. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
Ding X; Huang W; Peng Y; Fan H; Zhu Y; Liu X; Yang Y; Guo Q; Qiu L; Dai Y; Zou D; Jin F
Ann Hematol; 2020 Jun; 99(6):1331-1339. PubMed ID: 32382775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
